Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

geron - GERN

GERN

Close Chg Chg %
3.99 -0.01 -0.25%

Closed Market

3.98

-0.01 (0.25%)

Volume: 5.93M

Last Updated:

Dec 11, 2024, 4:00 PM EDT

Trade Now

Company Overview: geron - GERN

GERN Key Data

Open

$3.98

 Day Range

3.93 - 4.05

52 Week Range

1.64 - 5.34

 Market Cap

$2.41B

Shares Outstanding

604.50M

 Public Float

564.66M

Beta

0.51

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.32

Yield

0.00%

 Dividend

$0.15

EX-DIVIDEND DATE

Jul 22, 2014

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.19M

  

GERN Performance

1 Week
 
 1.27%
 
1 Month
 
 8.74%
 
3 Months
 
 -11.75%
 
1 Year
 
 76.89%
 
5 Years
 
 165.33%
 

GERN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About geron - GERN

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

GERN At a Glance

Geron Corp.
919 East Hillsdale Boulevard
Foster City, California 94404
Phone 1-650-473-7700 Revenue 237.00K
Industry Biotechnology Net Income -184,127,000.00
Sector Health Technology Employees 141
Fiscal Year-end 12 / 2024
View SEC Filings

GERN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 5,080.43
Price to Book Ratio 4.637
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.951
Enterprise Value to Sales 4,030.156
Total Debt to Enterprise Value 0.09

GERN Efficiency

Revenue/Employee 1,680.851
Income Per Employee -1,305,865.248
Receivables Turnover 0.143
Total Asset Turnover 0.001

GERN Liquidity

Current Ratio 3.159
Quick Ratio 3.159
Cash Ratio 3.098

GERN Profitability

Gross Margin -335.865
Operating Margin -81,832.911
Pretax Margin -77,690.717
Net Margin -77,690.717
Return on Assets -62.987
Return on Equity -112.291
Return on Total Capital -55.153
Return on Invested Capital -92.09

GERN Capital Structure

Total Debt to Total Equity 34.644
Total Debt to Total Capital 25.73
Total Debt to Total Assets 21.798
Long-Term Debt to Equity 15.349
Long-Term Debt to Total Capital 11.399
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Geron - GERN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
253.00K 1.39M 596.00K 237.00K
Sales Growth
-45.00% +450.59% -57.21% -60.23%
Cost of Goods Sold (COGS) incl D&A
- 783.00K 868.00K 1.03M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
935.00K 783.00K 868.00K 1.03M
Depreciation
935.00K 783.00K 868.00K 1.03M
Amortization of Intangibles
- - - -
-
COGS Growth
- - +10.86% +19.01%
-
Gross Income
- 610.00K (272.00K) (796.00K)
Gross Income Growth
- - -144.59% -192.65%
-
Gross Profit Margin
- +43.79% -45.64% -335.86%
2020 2021 2022 2023 5-year trend
SG&A Expense
76.23M 114.61M 138.28M 193.15M
Research & Development
51.49M 85.73M 95.52M 125.05M
Other SG&A
24.74M 28.88M 42.76M 68.10M
SGA Growth
+5.60% +50.34% +20.65% +39.68%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (60.00K)
-
EBIT after Unusual Expense
(76.85M) (114.00M) (138.55M) (193.94M)
Non Operating Income/Expense
2.00M 1.63M 3.53M 18.13M
Non-Operating Interest Income
1.83M 527.00K 2.53M 18.15M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
760.00K 3.74M 6.88M 8.31M
Interest Expense Growth
- +392.11% +84.01% +20.78%
Gross Interest Expense
760.00K 3.74M 6.88M 8.31M
Interest Capitalized
- - - -
-
Pretax Income
(75.62M) (116.11M) (141.90M) (184.13M)
Pretax Income Growth
-10.31% -53.55% -22.21% -29.76%
Pretax Margin
-29,888.14% -8,335.39% -23,808.89% -77,690.72%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(75.62M) (116.11M) (141.90M) (184.13M)
Minority Interest Expense
- - - -
-
Net Income
(75.62M) (116.11M) (141.90M) (184.13M)
Net Income Growth
-10.31% -53.55% -22.21% -29.76%
Net Margin Growth
-29,888.14% -8,335.39% -23,808.89% -77,690.72%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(75.62M) (116.11M) (141.90M) (184.13M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(75.62M) (116.11M) (141.90M) (184.13M)
EPS (Basic)
-0.2786 -0.3544 -0.3726 -0.3227
EPS (Basic) Growth
+22.72% -27.21% -5.14% +13.39%
Basic Shares Outstanding
271.46M 327.63M 380.78M 570.65M
EPS (Diluted)
-0.2786 -0.3544 -0.3726 -0.3227
EPS (Diluted) Growth
+22.72% -27.21% -5.14% +13.39%
Diluted Shares Outstanding
271.46M 327.63M 380.78M 570.65M
EBITDA
(75.98M) (113.22M) (137.68M) (192.91M)
EBITDA Growth
-5.92% -49.01% -21.61% -40.11%
EBITDA Margin
-30,030.83% -8,127.49% -23,101.01% -81,397.05%

Snapshot

Average Recommendation BUY Average Target Price 7.25
Number of Ratings 10 Current Quarters Estimate -0.033
FY Report Date 12 / 2024 Current Year's Estimate -0.262
Last Quarter’s Earnings -0.04 Median PE on CY Estimate N/A
Year Ago Earnings -0.32 Next Fiscal Year Estimate -0.07
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 7 10 10
Mean Estimate -0.03 -0.04 -0.26 -0.07
High Estimates 0.12 -0.01 -0.11 0.10
Low Estimate -0.12 -0.06 -0.35 -0.20
Coefficient of Variance -186.75 -40.49 -24.79 -137.44

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 7
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Geron - GERN

Date Name Shares Transaction Value
Jul 11, 2024 Andrew J. Grethlein EVP, Chief Operating Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.56 per share 0.00
Jul 11, 2024 Andrew J. Grethlein EVP, Chief Operating Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 11, 2024 Andrew J. Grethlein EVP, Chief Operating Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 11, 2024 Andrew J. Grethlein EVP, Chief Operating Officer 674,348 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.72 per share 1,159,878.56
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.63 per share 0.00
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer 155,400 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.3 per share 202,020.00
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer 20,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share 21,200.00
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer 112,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share 119,250.00
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer 87,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 13, 2024 Anil Kapur EVP, Corp Strategy & CCO 328,125 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 13, 2024 Anil Kapur EVP, Corp Strategy & CCO N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.64 per share 0.00
Jun 13, 2024 Anil Kapur EVP, Corp Strategy & CCO 421,875 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.06 per share 447,187.50
Jun 13, 2024 Faye Feller EVP, Chief Medical Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 6, 2024 John A. Scarlett Chairman, President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 6, 2024 John A. Scarlett Chairman, President and CEO; Director 600,000 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4 per share 2,400,000.00
Jun 6, 2024 John A. Scarlett Chairman, President and CEO; Director 600,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.54 per share 1,524,000.00
May 13, 2024 John F. McDonald Director 180,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Gaurav Aggarwal Director 180,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Susan M. Molineaux Director 180,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Geron in the News